MedTrace Logo

The Efficacy of Fenugreek Supplementation on Men's Health

NCT03528538 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2018-05-18

No results posted yet for this study

Summary

1. The problem: There is limited research on the use of herbal supplements in general, and fenugreek specifically, to improve male health, particularly to increase testosterone levels. As well, no located studies have examined the effects of fenugreek supplementation on healthy men's health-related quality of life, anxiety levels, and body composition.
2. Relevant research examined the effects of fenugreek supplementation with healthy men aged between 43 and 70 years of age. The researchers found that both total serum testosterone and free testosterone increased compared to placebo after 12 weeks of active treatment. The researchers concluded that fenugreek supplementation was a safe and effective treatment for reducing symptoms of possible androgen deficiency, improves sexual function and increases serum testosterone in healthy middle-aged to older men. Another study found that fenugreek supplementation improved aging male symptoms and testosterone levels remained in a normal range in healthy men aged 25 to 45 years.
3. The importance of this study: The importance of this study is to help determine if fenugreek supplementation affects testosterone levels, body composition, health-related quality of life, anxiety, and aging symptoms in healthy men aged 21 - 45 years.

Conditions

  • Aging
  • Testosterone Deficiency

Interventions

DIETARY_SUPPLEMENT

AlphaFen fenugreek 400 mg

A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.

DIETARY_SUPPLEMENT

AlphaFen fenugreek 500 mg

A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.

OTHER

Placebo

rice flour in a vegetable/ cellulose capsule

Sponsors & Collaborators

  • SPECNOVA LLC

    collaborator UNKNOWN

  • Jacksonville University

    lead OTHER

Principal Investigators

  • Heather Hausenblaus, PhD · Jacksonville University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-19
Primary Completion
2017-12-15
Completion
2017-12-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03528538 on ClinicalTrials.gov